The stock markets have been seesawing and many experts are as flummoxed. Here’s what leading investors Warren Buffett, Ray Dalio, and Howard Marks have to say.
Keep Reading →
July 3 - Hedge Funds, Insider Trading - Comments
Anyone looking to learn how a quant fund conquered the financial world should go out and buy Greg Zuckerman’s “The Man Who Solved the Market” when it’s released next week...
Keep Reading →
November 1 - Hedge Funds, Insider Trading - Comments
The stock market’s main gauges will rack up weekly gains of 2% or more, if they can just make it through today’s session unscathed.
Keep Reading →
May 11 - Hedge Funds, Insider Trading - Comments
Hedge fund manager David Einhorn said a shift in favor of value stocks may soon be coming even after his firm posted its worst underperformance in almost two decades.
Keep Reading →
February 21 - Hedge Funds, Insider Trading - Comments
Please follow Baker Bros. Advisors (if you aren't already doing so) to get real-time email alerts whenever we publish an article about Baker Bros.
Keep Reading →
February 7 - Hedge Funds - Comments
You can access the original SEC filing by clicking here.
Keep Reading →
May 18 - Hedge Funds - Comments
Equities have seen a pullback amid uncertainty regarding the Federal Reserve's plans to hike the interest rates.
Keep Reading →
September 14 - News - Comments
Seattle Genetics, Inc. (NASDAQ:SGEN) just reported second quarter financials, and the company is up nearly 10% on the data.
Keep Reading →
July 28 - News, Stock Analysis - Comments
While several hedge funds have suffered enormous losses this year due to their investments in biotech stocks, the performance of the leading biotech-focused hedge fund Baker Bros...
Keep Reading →
May 7 - Hedge Fund Analysis, Hedge Funds, News - Comments
Baker Bros. Advisors is a New York City-based fund launched in 2000 by Julian and Felix Baker.
Keep Reading →
February 25 - Hedge Funds, News - Comments
Fresh statistics reveal that the 50 most popular stocks among hedge funds lost 10% in 2015, which practically means that individual investors should have avoided to invest in...
Keep Reading →
February 24 - Hedge Funds, News - Comments
Given elite hedge funds have filed their latest 13F's, we have an opportunity to analyze what hedge funds like and what they don't like.
Keep Reading →
December 11 - Hedge Funds, News - Comments
Baker Bros. Advisors is one of the most famous healthcare-focused equity hedge funds in the world today.
Keep Reading →
December 9 - Hedge Fund Analysis, Hedge Funds, News - Comments
You don’t necessarily need millions of dollars to invest like an activist investor such as Carl Icahn or Bill Ackman.
Keep Reading →
November 23 - Hedge Fund Analysis, Hedge Funds, News - Comments
Generally, insider trading activity represents an important tool in the process of fundamental security analysis, as it can offer some insights on how insiders feel about the ...
Keep Reading →
November 9 - Insider Trading, News - Comments
Julian Baker and Felix Baker’s Baker Bros. Advisors continues to relentlessly add shares to its position in Seattle Genetics, Inc. (NASDAQ:SGEN).
Keep Reading →
September 16 - Hedge Funds, News - Comments
Julian Baker and Felix Baker's Baker Bros. Advisors’ top pick from the end of 2014 has paid off for the fund in a big way in 2015.
Keep Reading →
March 5 - Hedge Funds, News - Comments
Julian Baker and Felix Baker’s Baker Bros. Advisors recently disclosed an increase of around 929,700 shares to its position in Mirati Therapeutics, Inc. (NASDAQ:MRTX).
Keep Reading →
February 4 - Hedge Funds, News - Comments
Baker Bros. Advisors, the fund managed by Julian and Felix Baker disclosed changes in two of its activist positions last Thursday.
Keep Reading →
December 15 - Hedge Funds, News - Comments
In several new filings with the Securities and Exchange Commission, Julian and Felix Bakers' healthcare-focused fund Baker Bros.
Keep Reading →
November 12 - Hedge Funds, News - Comments
Baker Bros. Advisors, managed by Julian Baker and Felix Baker, have disclosed raising its stake in Seattle Genetics Inc. (NASDAQ:SGEN). In a new filing with the U.S.
Keep Reading →
May 19 - Hedge Funds, News - Comments
Julian Baker and Felix Baker’s hedge fund, Baker Bros. Advisors, has recently tweaked its holdings in ACADIA Pharmaceuticals Inc.
Keep Reading →
March 10 - Hedge Funds, News - Comments
Julian and Felix Baker's Baker Bros. Advisors has decreased its stake in MEI Pharma Inc (NASDAQ:MEIP) to 746,521 shares, from 1,130,317 shares revealed as held earlier.
Keep Reading →
January 2 - Hedge Funds, News - Comments
The healthcare sector is usually very attractive to investors, since the companies involved in it have a great potential to grow.
Keep Reading →
December 19 - Hedge Funds, News - Comments
Julian Baker and Felix Baker have increased their exposure to Seattle Genetics, Inc. (NASDAQ:SGEN) even higher.
Keep Reading →
December 17 - Hedge Funds, News - Comments
Legg Mason’s Bill Miller is struggling to find the ‘extraordinary’ value in the US he did last year, and said equity markets could rise even higher in 2014.
Keep Reading →
November 29 - Hedge Funds - Comments
In pharmacology, we don't only have to consider the actions of the drug on the body.
Keep Reading →
September 12 - News - Comments
At the moment, there are a multitude of metrics shareholders can use to monitor stocks. A pair of the most useful are hedge fund and insider trading sentiment.
Keep Reading →
September 10 - News - Comments
In late August, Amgen agreed to buy Onyx Pharmaceuticals in one of the worst-kept M&A secrets of the year.
Keep Reading →
September 9 - News - Comments
With second-quarter earnings season now in the books and about a month to go before third-quarter earnings kicks off, biotech savvy investors are in for a treat this week with...
Keep Reading →
September 9 - News - Comments
In the eyes of many investors, hedge funds are seen as overrated, old financial tools of a forgotten age.
Keep Reading →
August 28 - News - Comments
In today’s marketplace, there are a multitude of gauges market participants can use to analyze their holdings.
Keep Reading →
August 27 - News - Comments
While that's certainly not what Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) investors were hoping for -- at one point, after Amgen, Inc.
Keep Reading →
August 26 - News - Comments
In the 21st century investor’s toolkit, there are tons of metrics shareholders can use to track publicly traded companies.
Keep Reading →
August 26 - News - Comments
In the financial world, there are dozens of gauges shareholders can use to analyze stocks. Two of the most under-the-radar are hedge fund and insider trading sentiment.
Keep Reading →
August 26 - News - Comments
In today’s marketplace, there are a multitude of methods shareholders can use to monitor the equity markets.
Keep Reading →
August 25 - News - Comments
If you were to ask many investors, hedge funds are assumed to be useless, old investment tools of a period lost to current times.
Keep Reading →
August 23 - News - Comments
There's been plenty of buzz lately about the continuing saga of the possible buyout of Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) by Amgen, Inc. (NASDAQ:AMGN).
Keep Reading →
August 23 - News - Comments
Cancer is the target of a number of different biotech companies. Out of this lot, I consider Seattle Genetics, Inc. (NASDAQ:SGEN) to be one of the star performers.
Keep Reading →
August 6 - News - Comments
Global biotechnology industry revenue is expected to reach $262 billion this year showing growth of around 12.7% year over year.
Keep Reading →
July 22 - News - Comments
There are many biotech stocks that target cancer, but what is good about Celldex Therapeutics, Inc.
Keep Reading →
July 3 - News - Comments
Today, cancer is the second leading cause of death in the United States, accounting for nearly a quarter of all deaths in the country.
Keep Reading →
July 3 - News - Comments
Anticancer drugs typically damage normal cells as well as cancer cells.
Keep Reading →
July 2 - News - Comments
ACADIA Pharmaceuticals Inc.
Keep Reading →
July 2 - News - Comments
Mark your calendars Amarin Corporation plc (ADR) (NASDAQ:AMRN) investors.
Keep Reading →
June 20 - News - Comments
The cancer world has been abuzz after an exciting ASCO conference. Bristol Myers Squibb Co.
Keep Reading →
June 14 - News - Comments
One of the best ways that retail investors can try to decide which stocks will make for a promising investment is to look at what the hedge funds are doing.
Keep Reading →
June 10 - Hedge Funds - Comments
As I noted 11 weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
May 20 - News - Comments
As I noted seven weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
April 17 - News - Comments
The questions from analysts at the end of a company's conference call typically fall in the softball category.
Keep Reading →
March 17 - News - Comments
